Loading
A phase 2 trial of Dexamethasone, Methotrexate, Amivantamab and Lazertinib in non-small-cell lung cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.
Premedication to Reduce Amivantamab Associated Infusion Related Reactions is a phase 2 interventional study registered as NCT05663866 by Janssen Research & Development, LLC, with 68 participants enrolled, started 2023-05-18 and due to reach its primary completion in 2024-03-29. Interventions recorded: Dexamethasone, Montelukast, Methotrexate, Amivantamab and Lazertinib. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
68 enrolled.
95% CI 35.9 to 99.6; Figures from the ClinicalTrials.gov results section (first posted 2025-10-20), not from a publication · 95% CI 10.8 to 38.5 · 95% CI 38.4 to 88.2 · 95% CI 35.9 to 99.6
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Percentage of Participants With Infusion-related Reactions (IRRs) at Cycle 1 Day 1primary | Cohort A: Dexamethasone 4 Milligrams (mg) | 6 | 83.3% | - | - | link |
| Cohort A2: Dexamethasone 8 mg | 40 | 22.5% | ||||
| Cohort B: Montelukast 10 mg | 15 | 66.7% | ||||
| Cohort C: Methotrexate 25 mg | 6 | 83.3% |
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Lazertinib, Amivantamab, Johnson & Johnson, Bispecific antibodies and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, EGFR-mutated non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.
Shares Amivantamab, Johnson & Johnson, Bispecific antibodies, Non-small-cell lung cancer and the tag pipeline.